Introduction：Basic information about CAS 408504-26-7|Sergliflozin etabonate, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Sergliflozin etabonate |
|---|
| CAS Number | 408504-26-7 | Molecular Weight | 448.463 |
|---|
| Density | 1.3±0.1 g/cm3 | Boiling Point | 611.5±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C23H28O9 | Melting Point | / |
|---|
| MSDS | / | Flash Point | 206.8±25.0 °C |
|---|
Names
| Name | ethyl [(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-[2-[(4-methoxyphenyl)methyl]phenoxy]oxan-2-yl]methyl carbonate |
|---|
| Synonym | More Synonyms |
|---|
Sergliflozin etabonate BiologicalActivity
| Description | Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes[1]. |
|---|
| Related Catalog | Research Areas >>Metabolic DiseaseSignaling Pathways >>Membrane Transporter/Ion Channel >>SGLT |
|---|
| Target | SGLT2 |
|---|
| In Vivo | Sergliflozin etabonate (1、3、10、30 mg/kg；口服；一次) 以剂量依赖性方式显着降低 KK-Ay 小鼠的非空腹血糖水平[1]。 Sergliflozin etabonate (1.7、8.4、45.7 mg/kg饲料含有 0.001、0.005 和 0.025% sergliflozin etabonate；进食；每天服用，持续 9 周) 以剂量依赖的方式降低非空腹血糖水平并降低肝脏中的甘油三酯含量 在 KK-Ay 小鼠中[1]。 Animal Model: 14 weeks, Female KK-Ay mice[1] Dosage: 1, 3, 10, 30 mg/kg Administration: Oral; once Result: Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively. Animal Model: 4 weeks, Female KK-Ay mice[1] Dosage: 1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate Administration: Fed, daily for 9 weeks Result: Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice. |
|---|
| References | [1]. Katsuno K, et al. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104. |
|---|
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|
| Boiling Point | 611.5±55.0 °C at 760 mmHg |
|---|
| Molecular Formula | C23H28O9 |
|---|
| Molecular Weight | 448.463 |
|---|
| Flash Point | 206.8±25.0 °C |
|---|
| Exact Mass | 448.173340 |
|---|
| PSA | 123.91000 |
|---|
| LogP | 3.62 |
|---|
| Vapour Pressure | 0.0±1.8 mmHg at 25°C |
|---|
| Index of Refraction | 1.581 |
|---|
| InChIKey | QLXKHBNJTPICNF-QMCAAQAGSA-N |
|---|
| SMILES | CCOC(=O)OCC1OC(Oc2ccccc2Cc2ccc(OC)cc2)C(O)C(O)C1O |
|---|
Synonyms
| β-D-Glucopyranoside, 2-[(4-methoxyphenyl)methyl]phenyl 6-O-(ethoxycarbonyl)- |
| 2-(4-Methoxybenzyl)phenyl 6-O-(ethoxycarbonyl)-β-D-glucopyranoside |
| Sergliflozin etabonate |
| Sergliflozin |
